Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes

pharmafile | July 23, 2019 | News story | Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus 

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat influenza, herpes and human rhinovirus, the virus that causes the common cold.

The deal will see Gilead acquire the exclusive global rights to develop and commercialise novel small molecules against the three undisclosed targets.

The deal will see Novartis receive an upfront payment of an undisclosed amount and up to $291 million in milestone payments on reaching commercial and developmental milestones.

“Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said Dr John McHutchison, Gilead’s Chief Scientific Officer and Head of Research and Development.  

The deal will see Gilead build on its core competency of virology and infectious diseases. The Foster City-firm’s antiviral portfolio includes some of the most widely sued medicines for Hepatitis B (HBV), Hepatitis C (HCV) and HIV. The deal represents Gilead’s move into mass market therapeutic areas. 

Louis Goss

Related Content

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Latest content